Adjuvant hormone therapy after radical prostatectomy: Indications and results

Tumori

Volumn 83, Issue 2, 1997, Pages 567-575

  Ditonno, Pasquale ^a   Battaglia, Michele ^a   Selvaggi, Francesco Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Adjuvant therapy; Prostate cancer; Prostatectomy

Indexed keywords

CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; HORMONE; MEDROXYPROGESTERONE; PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDICATION; HUMAN; LYMPH NODE METASTASIS; MALE; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE;

EID: 0030848211     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169708300219     Document Type: Conference Paper

References (64)

1. Anscher M.S., Prosnitz L.R.: Radiotherapy vs hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy. Int. J. Radia. Oncol. Biol. Phys., 17: 953-958, 1989.
2. Bagshaw M.A., Cox R.S., Ray G.R.: Status of radiation treatment of prostate cancer at Stanford University. Natl. Cancer Inst. Monogr., 7: 47-60, 1988.
3. Beyer A., Leitenberger A., Altwein J.E.: Adjuvant hormonal therapy following radical prostatectomy. Eur. Urol., 24 (suppl 2): 51-56, 1993.
4. Boxer R.J., Kaufman J.J., Goodwin W.E.: Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients. J. Urol., 117: 208-213, 1977.
5. Brawn P., Kuhl D., Johnson C., Pandya P., McCord R.: Stage D1 prostate carcinoma: the histological appearance of nodal metastases and its relationship to survival. Cancer, 65: 538-543, 1990.
6. Carroll P.R. (Editorial): Laparoscopic urological surgery: differentiating what should be done from what can be done. J. Urol., 151: 1603-1604, 1994.
7. Carter G.E., Lieskovsky G., Skinner D.G.: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J. Urol., 142: 1266-1271, 1989.
8. Catalona W.J., Bigg S.W.: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J. Urol., 143: 538-544, 1990.
9. Catalona W.J., Fleishmann J., Menon M.: Pelvic lymph node status as predictor of extracapsular tumor extension in clinical stage B prostatic cancer. J. Urol., 129: 327-329, 1983.
10. Catalona W.J., Stein A.J.: Accuracy of frozen section detection of lymph node metastases in prostatic carcinoma. J. Urol., 127: 460-461, 1982.
11. Cheng W.S., Frydenberg M., Bergstralh E.J., Larson Keller J.J., Zincke H.: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology, 42: 283-291, 1993.
12. Cheng W.S., Frydenberg M., Bergstrahl E.J., Zincke H.: Prostate specific antigen levels after radical prostatectomy and immediate hormonal treatment for stage d1 prostate cancer are predictive of early disease outcome. Eur. Urol., 25: 189-193, 1994.
13. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Schnall M., Tomaszewski J.E., Wein A.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131-138, 1995.
14. De Vere White R., Paulson D.F., Glenn J.F: The clinical spectrum of prostate cancer. J. Urol., 117: 323-327, 1977.
15. deKernion J.B., Neuwirth H., Stein A., Dorey F., Stenzl A., Hannah J., Blyth B.: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J. Urol., 144: 700-703, 1990.
16. Ebert T., Schmitz-Drager B.J., Burrig K.F., Miller S., Pauli N., Kahn T., Ackermann R.: Accuracy of imaging modalities in staging the local extent of prostate cancer. Urol. Clin. North Am., 18: 3, 453-7, 1991.
17. Elder J.S., Jewett H.J., Walsh P.C.: Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J. Urol., 127: 704-706, 1982.
18. Epstein J.L., Walsh P.C., Brendler C.B.: Radical prostatectomy for impalpable prostate cancer. The Johns Hopkins experience with tumors found on transurethral resection (stage T1a and T1b) and on needle biopsy (stage T1c). J. Urol., 152: 1721-1729, 1994.
19. Fleshner N.E., Trachtenberg J.: Combination finasteride and flutamide in advanced carcinoma of prostate: effective therapy with minimal side effects. J. Urol., 154: 1642-1646, 1995.
20. Fleshner N.E., Trachtenberg J.: Sequential androgen blockade: a biological study in the inhibition of prostatic growth. J. Urol., 148: 1928-1937, 1992.
21. Frazier H.A., Robertson J.E., Paulson D.F.: Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J. Urol., 12: 308-313, 1994.
22. Frohmuller H.G.W., Theiss M., Mansek A., Wirth M.P.: Survival and quality of life of patients with stage D1 (T1-3pN1-2M0) prostate cancer. Prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur. Urol., 27: 202-206, 1995.
23. Gilson G., Parra R.O.: Prognosis of men with stage T3 prostate cancer: impact of early versus delayed adjuvant therapy. J. Urol., 153: 239A, 1995.
24. Golimbu M., Provet J., Al-Askari S.: Radical prostatectomy for stage D1 prostate cancer. Urology, 30: 427-435, 1987.
25. Hawkins C.A., Bergstralh E.J., Zincke H.: Influence of DNA ploidy on progression and survival in patients with stage pT3 prostate cancer following radical prostatectomy. J. Urol., 151: 255A, 1994.
26. Kamoshida S., Tsutsumi Y.: Extraprostatic localization of prostatic acid phosphatase and prostatic specific antigen: distribution in cloacogenic glandular epithelium and sex dependent expression in human anal gland. Hum. Pathol., 21: 1108-1111, 1990.
27. Killian C.S., Yang N., Emrich L.J., Vergas F.P., Kuriyama M., Wang M.C., Slack M.H., Papsidero L.D., Murphy G.P., Chu T.M.: Prognostic importance of prostate specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res., 45: 886-891, 1985.
28. Kramer S.A., Cline W.A., Farnham R.: Prognosis of patients with stage D1 prostatic adenocarcinoma. J. Urol., 125: 817-819, 1981.
29. Kuban D.A., El-Mahdi A.M., Schellhammer P.F.: Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology, 30: 420-426, 1987.
30. Kuban D.A., El-Mahdi A.M., Schellhammer P.F.: I125 interstitial implantation for prostate cancer. What have we learned 10 years later? Cancer, 63: 2415-2420, 1989.
31. Lange P.H., Ercole C.J., Lightner D.J.: The value of serum prostatic specific antigen before and after radical prostatectomy. J. Urol., 141: 873-879, 1989.
32. Leitenberger A., Baur H., Schneider W., Altwein J.E.: Adjuvant treatment after radical prostatectomy. Eur. Urol., 18 (suppl. 1): 189, 1990.
33. Lerner S.E., Blute M.L., Zincke H.: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J. Urol., 154: 1447-1452, 1995.
34. Lerner S.E., Seay T., Blute M.L., Bergstralh E.J., Barrett D., Zincke H.: PSA detected prostate cancer (clinical stage T1c): an interim analysis. J. Urol., 155: 821-826, 1996.
35. Lim A.J., Brandon A.H., Fiedler J., Brickman A.L., Boyer C.I., Raub W.A., Soloway M.S.: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J. Urol., 154: 1420-1425, 1995.
36. Martorana G., Oneto F., Curotto A., Bonamini A., Berti Riboli F., Tognoni P., Ubaldi L., Giuliani L.: Radical prostatectomy and adjuvant therapy in pathological C-D1 stage prostatic carcinoma: preliminary results. Eur. Urol., 18 (suppl 1): 190, 1990.
37. Mukamel E., deKernion J.B., Hannah J., Smith R.B., Skinner D.G. Goodwin W.E.: The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate. Cancer, 59: 1535-1538, 1987.
38. Myers R.P., Larson-Keller J.J., Bergstralh E.J., Zincke H., Oesterling J.E., Lieber M.M.: Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long term follow-up. J. Urol., 147: 910-915, 1992.
39. Ohori M., Wheeler T.M., Kattan M.W., Goto Y., Scardino P.T.: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 154: 1818-1824, 1995.
40. Partin A.W., Yoo J., Carter B.H., Pearson J.D., Chan D.W., Epstein J.I., Walsh P.C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110-114, 1993.
41. Pavone-Macaluso M., De Voogt H.J., Viggiano G., Barasolo E., Lardennois B., De Pauw M., Sylvester R.: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J. Urol., 136: 624-631, 1986.
42. Petros J.A., Catalona W.J.: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinical localized prostate cancer. J. Urol., 147: 1574-1575, 1992.
43. Prout G.R., Heaney J.A., Griffin P.P.: Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J. Urol., 124: 226-231, 1980.
44. Richie J.P.: Management of patients with positive margins following radical prostatectomy. Urol. Clin. North Am., 21: 4, 717-723, 1994.
45. Scardino P.T., Wheeler T.M.: Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. Natl. Cancer Inst. Monogr., 7: 95-103, 1988.
46. Schoeder F.H., Belt E.: Carcinoma of the prostate: a study of 213 patients with stage C tumors treated by total perineal prostatectomy. J. Urol., 114: 257-260, 1975.
47. Scott W.W., Boyd H.L.: Combined hormone control, therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J. Urol., 86: 101-104, 1966.
48. Skinner D.G., Lieskovsky G., Carter G.E.: Management of locally extensive cancer of the prostate without evidence of metastatic disease. Probl. Urol., 1: 99-105, 1987.
49. Stamey T.A., Kabalian J.N., Ferrari M., Yang N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Antiandrogen treated patients. J. Urol., 141: 1088-1090, 1989.
50. Stamey T.A., Villers A.A., McNeal J.E., Link P.C., Freiha F.S.: Positive surgical margins at radical prostatectomy: importance of the apical dissection. J. Urol., 143: 1166-1173, 1990.
51. Steinberg G.D., Epstein J.I., Piantadosi S., Walsh P.C.: Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J. Urol., 144: 1425-1432, 1990.
52. Stone N.N., Stock R.G., Unger P.: Indications for seminal vesicle biopsy and laparoscopic lymph node dissection in men with localized carcinoma of the prostate. J. Urol., 154: 1392-1396, 1995.
53. Takayama T.K., Vessella R.L., Brawer M.K.: The enhanced detection of persistent disease after prostatectomy with a new prostatic antigen immunoassay. J. Urol., 150: 374-378, 1993.
54. Terris M.K., McNeal J.E., Freiha F.S., Stamey T.A.: Efficacy of transrectal ultrasound guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J. Urol., 149: 1035-1039, 1993.
55. Tomlinson R.L., Currie P., Boyce W.H.: Radical prostatectomy: palliation for stage C carcinoma of the prostate. J. Urol., 117: 85-87, 1977.
56. Trapasso J.G., deKernion J.B., Smith R.B., Dorey F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy, J. Urol., 152: 1821-1825, 1994.
57. Tyrrell C.J., Altwein J.E., Klippel F., Varenhorst E., Lunglmayr, Boccardo F., Holdaway I.M., Haefliger J.M., Jordaan J.P., Sotarauta M.: A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J. Urol., 146: 1321-1326, 1991.
58. Vallencien G., Prapotnich D., Veillon B., Brisset J.M., André-Bourgaran J.: Seminal vesicle biopsies in the preoperative staging of prostate cancer. Eur. Urol., 19: 196-200, 1991.
59. Van den Ouden D., Davidson P.J.T., Hop W., Schroeder F.H.: Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J. Urol., 151: 646-651, 1994.
60. Yamada A.H., Lieskovsky G., Petrovich Z., Chen S.C., Groshen S., Skinner D.G.: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am. J. Clin. Oncol., 17: 277-85, 1994.
61. Zagars G.K., Von Eschenbach A.C., Johnson D.E., Oswald M.J.: Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer, 60: 1489-1499, 1987.
62. Zincke H., Bergstrahl E.J., Larson-Keller J.J., Farrow M.G., Myers R.P., Lieber M.M., Barrett D.M., Rife C.C., Gonchoroff N.J.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer, 70, 1 (suppl.): 311-323, 1992.
63. Zincke H., Fleming T.R., Furlow W.L.: Radical retropubic prostatectomy and pelvic lymphadenectomy for high stage cancer of the prostate. Cancer, 47: 1901-1910, 1981.
64. Zincke H., Oesterling J.E., Blute M.L., Bergstrahl E.J., Myers R.P., Barrett D.M.: Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 152: 1850-1857, 1994.